External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

APASL 2024

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Apr 22 / Roche
APASL 2024 One Liver Seminar
Transforming HCC Care: Now and the future.

Sign up or login to unlock the full suite of MEDICALLY features

Mar 28 / Roche and Genentech
NUC discontinuation outcomes in chronic hepatitis B in xalnesiran containing arms
Interim results from the phase 2 platform study PIRANGA on the nucleos(t)ide analogue discontinuation in patients with chronic hepatitis B treated with xalnesiran with or without an immunomodulator.

Sign up or login to unlock the full suite of MEDICALLY features

Mar 28 / Roche and Genentech
Efficacy and Safety of Xalnesiran with and without An Immunomodulator in Chronic Hepatitis B
Efficacy and safety results of the phase 2 platform study PIRANGA in NUC-suppressed patients with chronic hepatitis B who were treated with xalnesiran with or without an immunomodulator.
11:00 PM
Duration 59mins Kyoto, Japan
NUC discontinuation outcomes in chronic hepatitis B in xalnesiran containing arms
Jinlin Hou

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:18 PM
Duration 9mins Kyoto International Conference Hall, Room 05
Efficacy and Safety of Xalnesiran with and without An Immunomodulator in Chronic Hepatitis B
Jinlin Hou

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:30 PM
Duration 60mins Kyoto, Japan
APASL 2024 One Liver Seminar
Jacob George, Stephen Chan, Chun-Yen Lin

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar